When does Ozempic (semaglutide) patent/exclusivity end in the Orange Book—what does “2031” usually refer to?
Ozempic (semaglutide) is listed in FDA’s Orange Book for approved drug products and includes information such as patents and regulatory exclusivities tied to the approval. For many branded medicines, a specific year like 2031 commonly shows up because at least one listed patent (or a related exclusivity term) is scheduled to run through that period, meaning generic applicants typically must wait until that protection ends before marketing can begin. The Orange Book is the source that ties a listed protection to the drug’s specific FDA application and product label.
To confirm the exact “2031” date for Ozempic, you need to check the Orange Book entry for Ozempic and look at:
- the latest “Patent Expiration” date among listed Orange Book patents for the Ozempic product, and/or
- any listed “exclusivity” expiration dates (which are separate from patent terms and can differ).
What’s the difference between Orange Book patents vs. exclusivity dates?
Orange Book entries usually mix two types of protection:
- Patents: listed with an “expiration” date; these are specific to the approved product and can block approval or launch depending on the litigation/ANDA pathway and the Orange Book listing.
- Regulatory exclusivity: time-limited rights (for example, new drug or other exclusivity types) that can prevent FDA from approving certain generics or 505(b)(2) applications for that period.
A year like 2031 could correspond to one or the other (or both). That’s why two drugs can show the same “end year” on a quick scan but still differ in what actually blocks generic market entry.
How do patents and the ANDA process affect when generics can launch?
Even if a patent listed in the Orange Book expires in a given year, generic launch timing can be affected by:
- whether an ANDA has already been approved (or can be approved) before that expiry,
- how Orange Book patent certifications (and any required litigation) played out for that specific patent, and
- whether FDA can approve the application and the manufacturer can market immediately upon protection ending.
So the “patent expiration year” is often close to the earliest possible generic launch window, but not always a perfect match in practice.
How to verify the “2031” date yourself on the Orange Book (fast checklist)
To validate “Ozempic semaglutide patent expiration 2031” for your specific Ozempic strength/form:
1. Go to the FDA Orange Book search page.
2. Search for the brand name “Ozempic” (and/or the active ingredient “semaglutide”).
3. Open the Ozempic drug product record(s) matching the exact dosage form/strength.
4. In the “Patent Information” section, look for the listed “Expiration” dates and identify the latest one that corresponds to the product.
5. Check whether any “exclusivity” date is later than (or earlier than) the latest patent expiry.
6. If there are multiple entries, confirm you’re not mixing different semaglutide products (for example, different brands, strengths, or combination products).
Are there multiple semaglutide products—could “2031” be for a different one?
Yes. Semaglutide is marketed under multiple brands for different indications and dosing products. Orange Book dates can differ by:
- product (brand) name,
- dosage form/strength,
- and the underlying FDA application.
A common reason people see “2031” is that they’re looking at the wrong Ozempic/semaglutide listing or an associated patent table where the “expiration” applies to one specific product version rather than the exact one they care about.
Sources to cite (what you should check)
Because the Orange Book details are specific to each Ozempic product listing and can change as patents are added/updated, the most reliable citation is the specific Orange Book record for Ozempic and its listed patents/exclusivities.
If you paste the Orange Book URL (or the exact Orange Book listing rows showing “2031”), I can help you interpret which listed item corresponds to that year and what it likely means for generic entry timing.
Sources:
1. https://www.accessdata.fda.gov/scripts/cder/daf/ (FDA Orange Book search)